Genetic and Epigenetic Factors Associated with Immune-Related Adverse Events During Immune Checkpoint Inhibitor Therapy

Background/Objectives: Immune checkpoint inhibitors (ICIs) have transformed cancer treatment by restoring antitumor immune activity, but disruption of immune tolerance may result in immune-related adverse events (irAEs) involving multiple organs. The marked variability in irAE occurrence and phenotype suggests that treatment-induced immune activation acts on a background of pre-existing biological susceptibility. This narrative review evaluates genetic and epigenetic factors associated with irAE susceptibility and examines their potential contribution to risk assessment and the broader biology of immune dysregulation. Methods: A narrative review of the literature was conducted using PubMed/MEDLINE, Scopus, and Web of Science. Studies addressing HLA polymorphisms, germline variants, polygenic risk, DNA methylation, histone and chromatin regulation, and non-coding RNAs in relation to irAEs were considered. Particular emphasis was placed on human evidence, reproducibility, methodological limitations, and translational relevance. Results: Genetic studies provide the strongest human evidence for a contribution of inherited variation to selected irAE phenotypes, particularly through HLA and other immunoregulatory loci. Polygenic approaches may capture susceptibility more broadly than individual variants, but their predictive performance and generalizability remain insufficiently established. Epigenetic mechanisms, including DNA methylation and non-coding RNAs such as miR-146a, add a potentially dynamic layer of immune regulation. Interpretation of these findings is complicated by differences in irAE phenotype, timing of sampling, treatment exposure, population background, and tissue or cellular composition. Biological associations have not yet been translated into clinically validated predictive tools. Conclusions: Genetic and epigenetic variation may contribute to the biological background underlying susceptibility to irAEs, but current evidence does not support routine molecular risk testing before ICI therapy. Future progress will depend on prospective, multicenter studies that combine standardized clinical phenotyping with pre-treatment genetic information and longitudinal molecular profiling. The ultimate value of these approaches will be determined not simply by their ability to predict irAEs, but by whether they improve individualized risk assessment and clinical decision-making.

Authors

Institutions

Publication Details

Journal
Genes
Published
2026-11-16
DOI
https://doi.org/10.3390/genes17111438
Primary Topic
Cancer Immunotherapy and Biomarkers
Type
article
Field-Weighted Citation Impact
0.00
Controls
|||
ALL TIME
JAN
FEB
MAR
APR
MAY
JUN
JUL
AUG
SEP
OCT
NOV
article

Genetic and Epigenetic Factors Associated with Immune-Related Adverse Events During Immune Checkpoint Inhibitor Therapy

Grażyna Gromadzka, Maria Bendykowska, Paweł Domitrz
2 links
Genes
Cancer Immunotherapy and Biomarkers
article

Genetic and Epigenetic Factors Associated with Immune-Related Adverse Events During Immune Checkpoint Inhibitor Therapy

Grażyna Gromadzka, Maria Bendykowska, Paweł Domitrz
article en

Abstract

Background/Objectives: Immune checkpoint inhibitors (ICIs) have transformed cancer treatment by restoring antitumor immune activity, but disruption of immune tolerance may result in immune-related adverse events (irAEs) involving multiple organs. The marked variability in irAE occurrence and phenotype suggests that treatment-induced immune activation acts on a background of pre-existing biological susceptibility. This narrative review evaluates genetic and epigenetic factors associated with irAE susceptibility and examines their potential contribution to risk assessment and the broader biology of immune dysregulation. Methods: A narrative review of the literature was conducted using PubMed/MEDLINE, Scopus, and Web of Science. Studies addressing HLA polymorphisms, germline variants, polygenic risk, DNA methylation, histone and chromatin regulation, and non-coding RNAs in relation to irAEs were considered. Particular emphasis was placed on human evidence, reproducibility, methodological limitations, and translational relevance. Results: Genetic studies provide the strongest human evidence for a contribution of inherited variation to selected irAE phenotypes, particularly through HLA and other immunoregulatory loci. Polygenic approaches may capture susceptibility more broadly than individual variants, but their predictive performance and generalizability remain insufficiently established. Epigenetic mechanisms, including DNA methylation and non-coding RNAs such as miR-146a, add a potentially dynamic layer of immune regulation. Interpretation of these findings is complicated by differences in irAE phenotype, timing of sampling, treatment exposure, population background, and tissue or cellular composition. Biological associations have not yet been translated into clinically validated predictive tools. Conclusions: Genetic and epigenetic variation may contribute to the biological background underlying susceptibility to irAEs, but current evidence does not support routine molecular risk testing before ICI therapy. Future progress will depend on prospective, multicenter studies that combine standardized clinical phenotyping with pre-treatment genetic information and longitudinal molecular profiling. The ultimate value of these approaches will be determined not simply by their ability to predict irAEs, but by whether they improve individualized risk assessment and clinical decision-making.

GenesVol. 17(11)
Wojskowy Instytut Medyczny (PL), Cardinal Stefan Wyszynski University in Warsaw (PL)
Good health and well-being
Cancer Immunotherapy and Biomarkers
AI Navigator

Ask Laika to Summarize, Analyze, and Connect papers live on the map.

Summarize Papers & Methodologies

Extract key findings, datasets, and comparative methods across publications.

Benchmark Rankings & Visual Analytics

Rank top research institutions, authors, funders, topics, and journals by Field-Weighted Citation Impact (FWCI) and paper volume with instant charts.

Connect Distant Disciplines

Bridge topological clusters on the map to find hidden collaborative intersections.

Laika access coming soon